LncRNA LINC01833 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Patients with Lung Adenocarcinoma by Integrated Bioinformatics Analysis

Table 1

Clinicopathological features and LINC01833 expression in LUAD.

Characteristics	Low expression of LINC01833	High expression of LINC01833
n	267	268
Gender, n (%)			0.034
Female	130 (24.3%)	156 (29.2%)
Male	137 (25.6%)	112 (20.9%)
Age, n (%)			0.860
≤65	126 (24.4%)	129 (25%)
>65	132 (25.6%)	129 (25%)
T stage, n (%)			0.316
T1	97 (18.2%)	78 (14.7%)
T2	139 (26.1%)	150 (28.2%)
T3	21 (3.9%)	28 (5.3%)
T4	9 (1.7%)	10 (1.9%)
N stage, n (%)			0.045
N0	185 (35.6%)	163 (31.4%)
N1	43 (8.3%)	52 (10%)
N2	29 (5.6%)	45 (8.7%)
N3	0 (0%)	2 (0.4%)
M stage, n (%)			1.000
M0	180 (46.6%)	181 (46.9%)
M1	12 (3.1%)	13 (3.4%)
Pathologic stage, n (%)			0.069
Stage I	159 (30.2%)	135 (25.6%)
Stage II	55 (10.4%)	68 (12.9%)
Stage III	33 (6.3%)	51 (9.7%)
Stage IV	13 (2.5%)	13 (2.5%)
Age, median (IQR)	66 (59, 72)	65.5 (59, 73)	0.791